AdvanSource Biomaterials Corporation manufactures advanced polymer
materials which provide critical characteristics in the design and
development of medical devices. The Company’s
biomaterials are used in devices that are designed for treating a broad
range of anatomical sites and disease states. AdvanSource’s
business model leverages its proprietary materials science technology
and manufacturing expertise in order to expand its product sales and
royalty and license fee income. The Company is conducting a clinical
trial for regulatory approval at two sites in Europe for its CardioPass™
synthetic coronary bypass graft. More information about AdvanSource is
available at its website: www.advbiomaterials.com.
|
Company:
|
|
AdvanSource Biomaterials Corporation
|
|
|
|
Headquarters Address:
|
|
229 Andover Street
|
|
|
|
Wilmington, MA 01887
|
|
|
|
Main Telephone:
|
|
978-657-0075
|
|
|
|
Website:
|
|
www.advbiomaterials.com
|
|
|
|
Ticker/ISIN:
|
|
ASB(NYSE)/US00767T1097
|
|
|
|
Type of Organization:
|
|
Public
|
|
|
|
Industry:
|
|
Chemicals/Plastics
|
|
|
|
Key Executives:
|
|
CEO: Michael Adams
|
|
|
|
CFO: Eric Walters
|
|
|
|
AdvanSource Biomaterials
|
|
|
|
Contact:
|
|
Eric Walters
|
|
Phone:
|
|
978-657-0075
|
|
Email:
|
|
ewalters@advbiomaterials.com
|
|
|
|
Investor Relations
|
|
|
|
Contact:
|
|
David Volpe
|
|
Phone:
|
|
508-523-3141
|
|
Email:
|
|
david@clvllc.com
|
